However, one study has reported that downregulation of DIRAS1 expression is associated with decreased disease-free survival and overall survival in ovarian cancer patients.7 In addition, it has been suggested that DIRAS1 is a good predictor of overall survival in HER2+ breast cancer patients receiving neoadjuvant chemotherapy.18 Here, ERBB2 is linked to breast carcinoma.